Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the company will present data from ...

Biotech Vertex, known for its cystic fibrosis therapies, is set to report earnings on Feb. 12 ...

NAD⁺ is a coenzyme central to redox reactions, shuttling electrons in metabolic pathways and thereby supporting ATP ...

Detailed price information for Moleculin Biotech CS (MBRX-Q) from The Globe and Mail including charting and trades.

The FDA is expected to decide on treatments for acquired hypothalamic obesity, dry eye disease, primary biliary cholangitis, psoriatic arthritis, and severe leukocyte adhesion deficiency-I.

There is a history of studying relaxin in cardiovascular settings—Novartis started a phase 3 heart failure trial of a recombinant relaxin-2 peptide in 2013—but preclinical evidence of the molecule’s ...

Prosecutors say the executives were encouraging investors to buy more stocks for the drug knowing that it had been denied ...

Dewpoint Therapeutics doses first patient in phase 1a/2a clinical trial of DPTX3186 to treat advanced solid tumours: Boston Monday, February 9, 2026, 18:00 Hrs [IST] Dewpoint Ther ...

Every high-voltage electrical application in today’s world requires monitoring, whether it’s on the electrical grid and making sure that the nominal current is flowing downstream, or in a motor and ...

Researchers report that intermittent CO2 breathing can stimulate the brain’s glymphatic system. In a proof-of-concept study, ...

Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) stock rose 3% Tuesday morning after the company reported positive maintenance data from its REZOLVE-AD study for rezpegaldesleukin in patients with ...

BridgeBio's pipeline assets like encaleret and BBP-418 offer optionality but lack near-term cash flow and face regulatory ...